Patrick Duxbury > Gowling WLG > London, England > Lawyer Profile
Gowling WLG Offices
4 MORE LONDON RIVERSIDE
- Go to...
Partner and life sciences team leader, specialising in life sciences transactions of all kinds; also specialises in all aspects of transactional intellectual property law, including IP licensing, R&D collaborations, spin outs and IP strategy; deals include $520m collaboration between Astex Therapeutics and Novartis, $500m collaboration between Astex Therapeutics and Janssen, $1bn deal between Chroma Therapeutics and GSK and acting for GSK on their €400m deal with Morphosys A.G.; numerous transactions for MedImmune (including recent in-licence of a phase II antibody product from Amgen) and acting for various VCs on investments in life sciences companies, acting for Astellas on in-license of a phase III drug from Basilea and Chroma Theraputics on an out licence of the North and South American rights to their drug Tosedostat.
Trained Philip Conn & Co, Manchester; qualified 1993; partner Wragge & Co 1999; Wragge Lawrence Graham & Co, partner, 2014. Regular speaker at conferences and seminars on biotech and pharmaceutical licensing and collaborations; recent member of the Legal Expert network of the Association of British Pharmaceutical Industry. Presenter on the BIO advanced business development course in both the USA and Europe.
Licensing Executives Society; Association of the British Pharmaceutical Industry and the Biotechnology Industry Association.
Queen Elizabeth’s Grammar School; Newcastle University (1989 BSc Hons 2(1)); Chester College of Law (1991 CPE, Distinction; Law Society Finals, First Class Hons).
Football, cricket, skiing, walking, family.
Split between Birmingham and London, the ‘responsive, helpful, pragmatic and wise‘ IP team at Gowling WLG offers a global IP practice that handles a full range of transactional and contentious intellectual property issues. In particular, the team specialises in tech patent litigation, life sciences, sponsorships and designs litigation. Team leader Kate Swaine has a strong track record in international brand strategy and enforcement as well as being the co-head of IP for the firm internationally. Patrick Duxbury utilises his background as a microbiologist to expertly handle life science matters. Senior associate Michael Carter is also recommended for his expertise in IP licensing and enforcement.
Gowling WLG’s cross-departmental life sciences sector group handles the full spectrum of life sciences work encompassing transactions, patent disputes, regulatory issues and commercial work. The team counts several high-profile pharmaceutical companies on its client roster, including AstraZeneca and BioNTech. The firm also fields a distinct health and care team, which acts for a range of health and care service providers and investors, and is highly regarded for its real estate work relating to care homes and senior living facilities. Patrick Duxbury and Robert Breedon lead the group; Duxbury focuses on life sciences transactions and Breedon handles corporate work in the health and care sectors.
London > TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious)
The patent practice at Gowling WLG, led by Kate Swaine, is considered ‘a leading IP practice’ by clients, with ‘many bright minds and creative thinkers’. Areas of strength for the team stem from the patent litigation practice, covering the life sciences, manufacturing, engineering and technology sectors, as well as SEP and FRAND strategy and litigation. Clients from the telecoms, hi-tech, and food and beverage industries also trust the team to manage their patent portfolios in a non-contentious capacity. Alexandra Brodie is notable for her SEP/FRAND litigation expertise for telecoms and technology clients, while Paul Inman is a key name in the team for high-profile pharmaceuticals patent infringement and revocation expertise. Luke Kempton and Patrick Duxbury are go-to members of the team for IP transactional work. Also of note is the medical technology team, which fields the ‘excellent’ Jon Ball and ‘superb’ Huw Evans. Life sciences specialist Jenny Davies was recently promoted to partner, while patent litigator and fluent Japanese speaker Seiko Hakada joined the team from Norton Rose Fulbright.
- Leading individuals - London > Industry focus > Life sciences and healthcare
- Intellectual property: patents (contentious and non-contentious) - London > TMT (technology, media and telecoms)
- Life sciences and healthcare - London > Industry focus
Top Tier Firm Rankings
- Investment fund formation and management > Listed funds
- Projects, energy and natural resources > Water
- Corporate and commercial > Commercial contracts
- Dispute resolution > Commercial litigation: mid-market
- Real estate > Commercial property: development
- Real estate > Commercial property: investment
- Corporate and commercial > Equity capital markets – small-mid cap
- Projects, energy and natural resources > Infrastructure
- TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious)
- TMT (technology, media and telecoms) > Intellectual property: trade marks, copyright and design
- Industry focus > Life sciences and healthcare
- Employment > Pensions (non-contentious)
- Employment > Pensions: dispute resolution
- Industry focus > Retail and consumer
- Real estate > Commercial property: corporate occupiers
- Real estate > Construction: contentious
- Real estate > Construction: non-contentious
- Industry focus > Emerging markets
- Corporate and commercial > EU and competition: trade, WTO anti-dumping and customs
- Crime, fraud and licensing > Fraud: civil
- Employment > Health and safety
- Public sector > Healthcare
- Projects, energy and natural resources > Mining and minerals
- Real estate > Planning
- Projects, energy and natural resources > Power (including electricity, nuclear and renewables)
- Real estate > Property litigation
- Transport > Rail
- Investment fund formation and management > Real estate funds
- Private client > Contentious trusts and probate
- TMT (technology, media and telecoms) > Fintech
- TMT (technology, media and telecoms) > IT and telecoms
- Corporate and commercial > M&A: lower mid-market deals, £50m-£500m
- TMT (technology, media and telecoms) > Media and entertainment (including media finance)
- Corporate and commercial > Private equity: transactions - mid-market deals (up to £250m)
- Real estate > Property finance
- Real estate > Social housing: finance
- Industry focus > TMT
- Corporate and commercial > Venture capital
- Public sector > Administrative and public law
- Dispute resolution > Banking litigation: investment and retail
- Real estate > Environment
- Corporate and commercial > EU and competition
- Corporate and commercial > Financial services: contentious
- Corporate and commercial > Financial services: non-contentious/regulatory
- Dispute resolution > International arbitration